Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. Issue 1 (2nd January 2021)

• Record Type: Journal Article
• Authors: Krattinger, Regina; Ramelyte, Egle; Dornbierer, Joëlle; Dummer, Reinhard
• Is Part Of: Expert review of clinical pharmacology. Volume 14:Issue 1(2021)
• Page Start: 9
• Page End: 23
• Publication Date: 2021-01-02
• Subjects: Cutaneous melanoma -- single-agent therapy -- monotherapy -- combination therapy -- immunotherapy -- targeted therapy -- adjuvant treatment -- neoadjuvant treatment; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2019.1650641
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction : The development of immunotherapies and targeted therapies has changed the treatment approach in resectable, nonresectable, and metastatic melanoma. Because of their different pharmacological profiles, immunotherapies and/or targeted therapies have been studied in various combinations. Areas covered : We reviewed PubMed for most important clinical trials investigating efficacy and tolerability of combinatorial and single-agent approaches for the treatment of melanoma that were published up to June 2019. We discuss the most promising therapy approaches and highlight challenges of melanoma treatment. Expert opinion : Combinatorial approaches seem to be very promising in the treatment of resectable and advanced melanoma. Currently, dual immune checkpoint inhibition (ICI) with nivolumab and ipilimumab offers the best first-line treatment option for patients with BRAF -wt and -mutated, advanced melanoma. It is therapy of choice in younger patients with good ECOG performance status and poor prognostic features, whereas ICI monotherapy should be preferred in elderly patients with advanced melanoma. Benefit-risk ratio, patient's QoL and expectations, as well as treatment costs have to be considered in the choice of treatment. However, to elucidate mechanisms of resistance, biomarkers of response and to better define personalized strategies in the treatment of cutaneous melanoma, larger clinical trials comparing combined versus sequential therapies are necessary.